Competition comission clears Sun-Ranbaxy deal but tells it to sell off 7 brands

Firstpost reports that the drug-makers Sun Pharma and Ranbaxy got fair trade watchdog CCI's {Competition commission of India} approval on Monday for their long-pending USD 4-billion merger, but with a condition that they will have to modify the deal by divesting seven key products to address monopoly concerns.

This move would create the country's largest pharmaceutical company post the merger between Sun Pharma and Ranbaxy Laboratories.
Under the conditions, Sun Pharma will divest products involving Lueprorelin. The divest products will include Tamplet and Lupride.

On the other hand, Ranbaxy Laboratories will divest products such as Raciper L, Terlibax, Triolvance, Olanex F and Rosuvas EZ.

Source:
http://firstbiz.firstpost.com/corporate/cci-clears-sun-ranbaxy-deal-but-tells-it-to-sell-off-7-brands-112308.html

http://zeenews.india.com/business/news/companies/cci-approves-sun-pharma-ranbaxy-deal-creates-india-s-largest-pharma-co_113679.html